中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
THE CHINESE JOURNAL OF CLINICAL PHARMACOLOGY
2015年
12期
1106-1108
,共3页
利伐沙班%髋关节置换术%下肢静脉血栓%低分子肝素%安全性
利伐沙班%髖關節置換術%下肢靜脈血栓%低分子肝素%安全性
리벌사반%관관절치환술%하지정맥혈전%저분자간소%안전성
rivaroxaban%hip arthroplasty%deep venous thrombosis%low molecular heparin%safety
目的：评价髋关节置换术后利伐沙班预防下肢深静脉血栓的疗效与安全性。方法入选进行髋关节置换术的患者63例，并随机分为利伐沙班组31例（试验组）和低分子肝素组32例（对照组）。试验组术后6 h口服利伐沙班10 mg? d－1，连用35 d。对照组术后12 h皮下注射低分子肝素4100 U抗凝，连续14 d。记录2组患者围手术期出血量、血小板计数及凝血功能指标。术后随访3个月，比较2组患者下肢深静脉血栓发生率。结果试验组30例获得随访，术后3个月发生下肢深静脉血栓4例，发生率为13．3％；对照组31例获得随访，发生下肢深静脉血栓5例，发生率为16．2％，2组患者下肢深静脉血栓发生率差异无统计学意义（P＞0．05）。2组患者治疗前至治疗后14 d，血小板及凝血指标均无明显变化（ P ＞0．05）。试验组患者围手术期出血量为（1320．6±202．4）mL，对照组出血量为（1301．1±232．6）mL，差异无统计学意义（P＞0．05）。结论利伐沙班可有效降低髋关节置换术后下肢深静脉血栓发生风险，与低分子肝素疗效相当，且不增加出血风险。
目的：評價髖關節置換術後利伐沙班預防下肢深靜脈血栓的療效與安全性。方法入選進行髖關節置換術的患者63例，併隨機分為利伐沙班組31例（試驗組）和低分子肝素組32例（對照組）。試驗組術後6 h口服利伐沙班10 mg? d－1，連用35 d。對照組術後12 h皮下註射低分子肝素4100 U抗凝，連續14 d。記錄2組患者圍手術期齣血量、血小闆計數及凝血功能指標。術後隨訪3箇月，比較2組患者下肢深靜脈血栓髮生率。結果試驗組30例穫得隨訪，術後3箇月髮生下肢深靜脈血栓4例，髮生率為13．3％；對照組31例穫得隨訪，髮生下肢深靜脈血栓5例，髮生率為16．2％，2組患者下肢深靜脈血栓髮生率差異無統計學意義（P＞0．05）。2組患者治療前至治療後14 d，血小闆及凝血指標均無明顯變化（ P ＞0．05）。試驗組患者圍手術期齣血量為（1320．6±202．4）mL，對照組齣血量為（1301．1±232．6）mL，差異無統計學意義（P＞0．05）。結論利伐沙班可有效降低髖關節置換術後下肢深靜脈血栓髮生風險，與低分子肝素療效相噹，且不增加齣血風險。
목적：평개관관절치환술후리벌사반예방하지심정맥혈전적료효여안전성。방법입선진행관관절치환술적환자63례，병수궤분위리벌사반조31례（시험조）화저분자간소조32례（대조조）。시험조술후6 h구복리벌사반10 mg? d－1，련용35 d。대조조술후12 h피하주사저분자간소4100 U항응，련속14 d。기록2조환자위수술기출혈량、혈소판계수급응혈공능지표。술후수방3개월，비교2조환자하지심정맥혈전발생솔。결과시험조30례획득수방，술후3개월발생하지심정맥혈전4례，발생솔위13．3％；대조조31례획득수방，발생하지심정맥혈전5례，발생솔위16．2％，2조환자하지심정맥혈전발생솔차이무통계학의의（P＞0．05）。2조환자치료전지치료후14 d，혈소판급응혈지표균무명현변화（ P ＞0．05）。시험조환자위수술기출혈량위（1320．6±202．4）mL，대조조출혈량위（1301．1±232．6）mL，차이무통계학의의（P＞0．05）。결론리벌사반가유효강저관관절치환술후하지심정맥혈전발생풍험，여저분자간소료효상당，차불증가출혈풍험。
Objective To evaluate the efficacy and safety of rivaroxaban on anti -deep venous thrombosis for patients with hip arthroplasty. Methods A total of 63 cases who scheduled for hip arthroplasty were recruited and were randomly divided into treatment group ( n=31 ) and control group ( n =32 ) .Patients in treatment group were administered with rivaroxaban 10 mg? d-1 6 h after surgery orally qd for 35 days, and patients in the control group were injected with low molecular heparin 4100 U 12 h after surgery for 14 days.The data of blood loss, blood transfusion rate and deep venous thrombosis risk were compared between the two groups.Results There were 30 patients finishing the treatment of 3 months follow -up in treatment group with the incidence of deep venous thrombosis being 13.3%.There were 31 cases finishing the 3 months follow-up in the control group with the incidence of deep venous thrombosis being 16.2%.There was no statistical difference between the two groups (P>0.05).The platelet and coagulation function change of the two groups were not statistically different before and after the treatment ( P>0.05 ) .The blood loss was ( 1320.6 ±202.4 ) mL and (1301.1 ±232.6) mL in treatment group and control group respectively with no statistical difference ( P>0.05 ) .Conclusion Rivaroxaban can significantly decrease the risk of deep vein thrombosis in patients undergoing hip arthroplasty without increasing the risk of bleeding, similar to the efficacy of low molecular heparin.
